Pan-cancer analyses of NFKB2 expression and its prognostic significance in the TCGA database. by Yu Zhang (12946)

Subjects:

Association of covariates and COPD risk. by Yushan Shi (16440272)

Subjects:

Significant clusters: Coronal PET images showing brain regions with significant (p < 0.001 and K > 50) metabolic inhibition (A-G) and activation (H-I) in rats following cocaine sel... by Christopher Rowan (21499924)

Videofluoroscopic swallowing study parameters. by Rie Asayama (693361)

Subjects:

Interventions for Psychological Stress in Pregnant African American Women: A Scoping Review by Taleah A. Frazier (22423294)

Subjects:

Mean muscle activation patterns across the gait cycle during walking with mediolateral (ML) forces for <i>A)</i> able-bodied individuals and <i>B)</i> individuals after stroke duri... by Sanne Ettema (18786312)

S1 File - Utilization of psychotropic drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 pandemic by Jelena Filimonovic (22305307)

Subjects:

Anion-Assisted Glycosylation of Galactose: A Computational Study by Kerli Tali (22769704)

Subjects:

Mean scores and 95% CI of mental health symptoms, COVID-19 admissions and effect size during follow-up. by A. H. Ayesha Lavell (16734002)

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Additional file 3 of Single-cell profiling reveals a reduced epithelial defense system, decreased immune responses and the immune regulatory roles of different fibroblast subpopula... by Lin Lin (46073)

“…P values were calculated via the two-sided Wilcoxon test. ns, not significant, **, P < 0.01 and ****, P < 0.0001. (G) Feature plot showing LDLR expression levels in C1Q+ macrophages between CAG and control samples.…”

Comparison of W_max (A), the changes in V_E (B), and W_VT (C) among the three oxygen conditions. by Kazufumi Hisamoto (21416905)

Subjects: